Johnson & Johnson Introduces Its Cerenovus Neurovascular Business

 

July 24, 2017—Johnson & Johnson Medical Devices Companies announced the introduction of Cerenovus, its neurovascular business, at the Society of NeuroInterventional Surgery's 14th annual meeting in Colorado Springs, Colorado. Cerenovus will focus on delivering therapies for hemorrhagic and ischemic stroke patients.

Cerenovus’s neurovascular product portfolio was recently expanded with the acquisitions of Pulsar Vascular Inc., which specializes in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi, which offers the EmboTrap revascularization platform for the treatment of acute ischemic stroke.

Cerenovus is part of DePuy Synthes Products, Inc. within the Johnson & Johnson Medical Devices Companies segment.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.